376 related articles for article (PubMed ID: 16142501)
1. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Feldstein AC; Elmer PJ; Nichols GA; Herson M
Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
[TBL] [Abstract][Full Text] [Related]
2. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
3. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
5. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.
Solomon DH; Katz JN; Jacobs JP; La Tourette AM; Coblyn J
Arthritis Rheum; 2002 Dec; 46(12):3136-42. PubMed ID: 12483716
[TBL] [Abstract][Full Text] [Related]
6. Barriers in the management of glucocorticoid-induced osteoporosis.
Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
McKeown E; Bykerk VP; De Leon F; Bonner A; Thorne C; Hitchon CA; Boire G; Haraoui B; Ferland DS; Keystone EC; Pope JE;
Rheumatology (Oxford); 2012 Sep; 51(9):1662-9. PubMed ID: 22539481
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
9. Management of glucocorticoid-induced osteoporosis in male veterans.
Elliott ME; Farrah RM; Binkley NC; Carnes ML; Gudmundsson A
Ann Pharmacother; 2000 Dec; 34(12):1380-4. PubMed ID: 11144692
[TBL] [Abstract][Full Text] [Related]
10. Trends in prevention of glucocorticoid-induced osteoporosis.
Saag KG; Gehlbach SH; Curtis JR; Youket TE; Worley K; Lange JL
J Rheumatol; 2006 Aug; 33(8):1651-7. PubMed ID: 16845707
[TBL] [Abstract][Full Text] [Related]
11. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting.
Yood RA; Harrold LR; Fish L; Cernieux J; Emani S; Conboy E; Gurwitz JH
Arch Intern Med; 2001 May; 161(10):1322-7. PubMed ID: 11371261
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012.
Albaum JM; Lévesque LE; Gershon AS; Liu G; Cadarette SM
Osteoporos Int; 2015 Dec; 26(12):2845-52. PubMed ID: 26138581
[TBL] [Abstract][Full Text] [Related]
13. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan.
Chitre MM; Hayes W
J Manag Care Pharm; 2008 Apr; 14(3):281-90. PubMed ID: 18439050
[TBL] [Abstract][Full Text] [Related]
14. Update on glucocorticoid-induced osteoporosis.
Maricic M
Rheum Dis Clin North Am; 2011 Aug; 37(3):415-31, vi. PubMed ID: 22023900
[TBL] [Abstract][Full Text] [Related]
15. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
16. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice.
Ledwich LJ; Clarke K
J Clin Rheumatol; 2009 Mar; 15(2):61-4. PubMed ID: 19265346
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
[TBL] [Abstract][Full Text] [Related]
19. Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Song BW; Kim AR; Kim MA; Kim HS; Lee SG
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208647
[No Abstract] [Full Text] [Related]
20. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
